January 4, 2019
BerGenBio doses first patient in Phase II monotherapy study of bemcentinib in high-risk MDS & AML
BerGenBio ASA has been dosed the first patient with bemcentinib, in an investigator-initiated phase II trial, sponsored by GWT-TUD GmbH, a specialist cancer clinical research institution associated with the University of Dresden, Germany.